Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan in Metastatic Medullary Thyroid Cancer
NCT00100828Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2004
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan in Medullary Thyroid Cancer (MTC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Nov 2004; status: terminated.
02
Drugs
irinotecan
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT00100828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00100828.